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 Abstract 
Context Appropriate glucocorticoid replacement therapy in adrenal insufficiency (AI) is crucial, 
given the risks of chronic under- or overtreatment, particularly in patients on multiple medications. 
Salivary sampling allows for non-invasive, stress-free cortisol measurement.  
Objective To determine whether salivary cortisol measurement is helpful in assessing the adequacy 
of glucocorticoid therapy with cortisone acetate (CA) in patients with secondary AI.  
Design A prospective cohort study at the Endocrinology Unit of Padua University Hospital.  
Methods Six samples of salivary cortisol were collected from 28 patients with secondary AI on CA 
treatment and from 36 healthy volunteers at fixed times of the day, and used to calculate salivary 
cortisol levels at each time point and the area under the curve (AUC) across the different sampling 
times.  
Results Salivary cortisol levels were lower in patients than in controls in the morning but no 
differences were found in the afternoon or at night before resting. Salivary cortisol levels were 
higher in patients immediately following CA administration. Ten patients showed an AUC above 
the 97.5th percentile of controls, without clinical signs of hypercortisolism, and salivary cortisol 
levels 90 min after each dose of CA predict the AUC. All patients had severe GH deficiency and 
there were no differences in salivary cortisol levels or AUC between patients treated or not with 
GH.  
Conclusions Two salivary cortisol determinations, able to predict the daily AUC, may allow for 
assessing the adequacy of glucocorticoid replacement therapy in secondary AI and for identifying 
cases of over- or undertreatment.  
 
 
Introduction 
Optimizing glucocorticoid replacement therapy in adrenal insufficiency (AI) is a clinical challenge 
because undertreatment may lead to acute frank AI or chronic fatigue, while chronic glucocorticoid 
excess may cause obesity, hypertension, diabetes, and osteoporosis (1). Optimal replacement should 
produce cortisol concentrations that mirror the circadian cortisol rhythm (2), but available 
immediate-release glucocorticoid preparations only partially replicate the physiological cortisol 
profile (3); expertise with modified-release hydrocortisone (HC) tablets is still inadequate (4, 5). 
Secondary AI coexists with other pituitary hormone deficiencies; their replacement therapies may 
interfere with glucocorticoid metabolism and action (6, 7, 8, 9). A number of methods (urinary free 
cortisol, serum cortisol, or clinical score) have been suggested for assessing the adequacy of 
glucocorticoid replacement, but there is no consensus about the most reliable in clinical practice (1, 
3, 10, 11).  
Salivary steroids are a non-invasive, easily repeated, stress-free way to measure circulating free 
hormone levels (12, 13), recently recommended for assessing cortisol profiles in healthy people (14, 
15) and in patients with hypothalamic–pituitary–adrenal (HPA) axis disorders (16, 17).  
HC may represent the most physiological replacement therapy, but even when it is given three times 
a day, the resulting serum cortisol profile only partially replicates the circadian cortisol rhythm of 
healthy people. Serum cortisol peaks after taking HC, and then drops to lower than normal levels 
before the next dose; there is no night-time rise, so patients wake up with very low cortisol levels 
that contribute to early morning fatigue, a major drawback of current replacement regimes (3, 18). 
Salivary cortisol assays have been suggested for assessing HC-based glucocorticoid replacement, 
but literature data differ in terms of its reliability (19, 20, 21, 22). Cortisone acetate (CA) is an oral 
glucocorticoid that needs hepatic conversion to cortisol by the enzyme 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1). CA is more readily available than HC in Italy and other 
European countries, and is usually administered twice daily in secondary AI. On CA therapy, serum 
profiles seem to have lower cortisol peaks and also tends to decline more slowly than on HC 
therapy (18). One report has claimed that CA has metabolic advantages (on HbAlc and waist-to-hip 
ratio (WHR)) over HC, particularly in patients with hypopituitarism treated with recombinant 
human GH (rhGH) (23).  
A more precise estimation of endogenous cortisol production rate, believed to be around 9–
11 mg/m2 per day (24), has recently led to a reduction in the dosage of glucocorticoid replacement 
therapy (1, 2). How best to assess and adjust each patient's glucocorticoid therapy to avoid the risk 
of mild, but chronic under- or overtreatment remains, however, a matter of debate.  
The aim of our study was to assess the daily cortisol profile in healthy subjects and patients with 
secondary AI being treated with CA by six sequential salivary cortisol determinations, with a view 
to establishing the reliability of this method for deciding each individual's dosage, and to examine 
the influence of rhGH replacement treatment.  
 
Materials and methods 
Patients and protocol 
We recruited 28 outpatients with hypopituitarism, 17 male and 11 female (M/F ratio 1.5, age 54±18 
years), from January to December 2010, at the Endocrinology Unit of Padua. Their clinical features 
and hormone replacement therapies are summarized in Table 1. Secondary AI was diagnosed 
clinically and confirmed biochemically (with basal serum morning cortisol under 138 nmol/l in 12 
patients or inadequate cortisol response (considered as cortisol below 440 nmol/l) to a standard or 
low-dose ACTH test (25) in the other 16 subjects), and the patients had been taking the same CA 
replacement dose for at least 6 months before enrollment. CA dose was first based upon the body 
surface area (BSA) and then adapted according to well-being of the patient, serum 
sodium/potassium, blood pressure, glycemia, and urinary free cortisol levels. All patients had 
normal renal and liver function and showed no clinical or biochemical signs of iatrogenic 
hypercortisolism (e.g. newly diagnosed or worsening hypertension, obesity, impaired fasting 
glucose, hypokalemia, capillary fragility, or abdominal striae). None of the patients suffered from 
nausea, vomiting, diarrhea, intestinal pain, sleep disturbance, or headache over the last 6 months of 
replacement therapy, judging from their routinely recorded medical history. None of them had 
gastrointestinal disorders that might interfere with CA absorption (such as celiac disease or 
autoimmune gastritis). The mean daily dose of CA was 22.8±4.9 mg/day (median 21.9; range 
18.75–37.5), which corresponded on average to 12 mg/m2 of CA (the equivalent dose of HC is 
9.6 mg/m2). All patients took CA twice a day, the major part of the daily dose in the morning at 
wake up and the lower in the afternoon; only a few patients received therapy divided into two equal 
doses (CA regimens: 13 patients 12.5+6.25 mg/day, four patients 18.75+6.25 mg/day, two patients 
25+6.25 mg/day, two patients 25+12.5 mg/day, and seven patients 12.5+12.5 mg/day).  
Table 1 Clinical details of the patients. 
GH deficiency (GHD) was confirmed in all patients by a GHRH+arginine stimulation test. We 
considered severe GHD when the GH peak was below cut-off limits based upon BMI: for BMI 
<25 kg/m2, a peak of GH ≤11.5 μg/l; for BMI 25–30 kg/m2, a peak of GH ≤8 μg/l; for BMI 
>30 kg/m2, a peak of GH ≤4 μg/l (26); IGF1 levels in patients receiving rhGH therapy were between 
the 50th and 97.5th percentile of normal controls matched for sex and age (27). The diagnosis of 
other hormone deficiencies (central hypothyroidism or hypogonadism) was based on low pituitary 
hormone levels with low serum free thyroxine (fT4) or gonadal steroid hormones. Adequacy of 
replacement therapy was documented in all patients with secondary hypothyroidism by fT4 levels in 
the normal range, whereas estradiol levels in the range for the follicular phase in pre-menopausal-
aged women and total testosterone levels in the normal range for adult men suggested an adequate 
substitutive therapy (estrogen replacement route was transdermal for two women and oral for other 
two women, whereas testosterone therapy was by long-acting injection for four men and 
transdermal for nine men).  
In our patients, we measured weight, height, and waist and hip circumference. We calculated BMI 
as kg/m
2
 (BMI <25 n=16, 25–30 n=11, 30–35 n=1, 35–40 n=1, >40 n=0), WHR as waist/hip 
circumference (classifying patients with Canoy (28) value: female with WHR ≥0.8 n=3, male with 
WHR ≥0.95 n=5), and BSA by the DuBois and DuBois formula 
(0.007184×weightkg
0.425
×heightcm
0.725
) (29).  
Thirty-six healthy volunteers, 21 male and 15 female (M/F ratio 1.4, age 49±16 years), matched for 
mean age, sex, BMI class (<25 n=18, 25–30 n=14, 30–35 n=3, 35–40 n=1, >40 n=0), mean WHR 
(female with WHR ≥0.8 n=5, male with WHR ≥0.95 n=10), and mean BSA, provided clinical data 
and saliva samples during a day of normal activity. None of them were taking exogenous 
glucocorticoids or drugs that might interfere with the HPA axis; female volunteers were not taking 
oral or transdermal contraceptives and were investigated in the early follicular phase of the 
menstrual cycle.  
The study protocol was approved by our local ethics committee, and all patients and healthy 
controls gave written informed consent.  
 
 
Salivary sample collection and analyses 
Healthy volunteers and patients collected six salivary samples at home the first in the morning on 
waking (labeled F 0), then 1 h and 30 min (F 1.5), 7 h (F 7), 8 h and 30 min (F 8.5), 12 h (F 12), and 
14 h (F 14) after. Patients' F 0 and F 7 collections were obtained before the morning and afternoon 
CA doses (all patients received CA at least 30 min before the meal). During the course of the day, 
each saliva sample was collected into cotton-based sampling devices contained inside plastic 
syringes using the Salivette commercial device (Sarstedt, Numbrecht, Germany). Patients and 
volunteers were advised to soak the absorbent cotton with saliva for 2 or 3 min, with the sample 
then placed in a syringe and kept at +4 °C. Samples were collected at least 30 min before taking a 
meal or drink to avoid any source of food or blood contamination; patients and healthy volunteers 
brushed their teeth at least 30 min before collecting their saliva and avoided smoking or eating 
licorice on the day of saliva collection. After centrifugation, we obtained sufficient saliva volume in 
all samples (at least 1 ml), and then stored at −20 °C until assay with a commercially available RIA 
kit (Radim, Rome, Italy). The assay sensitivity was 0.5 ng/ml. The intra and inter assay variation 
was 3 and 9% respectively. Regarding specificity, this cortisol assay does not show cross-reaction 
with cortisone, desoxycorticosterone, corticosterone, estradiol, testosterone, and 17 
hydroxyprogesterone. Coefficients of variation in the high and in the low range were respectively of 
7 and 4%. To assess endogenous daily cortisol secretion in healthy controls and glucocorticoid 
exposure in patients, we computed the area under the curve (AUC) for salivary cortisol levels at the 
different time points with respect to the ground (AUC0–14), according to the trapezoidal formula 
proposed by Pruessner et al. (30). We divided the day being examined into two different periods of 
7 h, called AUC0–7 (from F 0 to F 7) and AUC7–14 (from F 7 to F 14).  
We considered the 2.5th and 97.5th percentiles of the AUC0–14, AUC0–7, and AUC7–14 in healthy 
subjects as lower and upper limits of normality, so patients were classed as undertreated if the 
AUC0–14 was below the 2.5th percentile of healthy controls or overtreated if it was above the 97.5th 
percentile of healthy controls.  
Statistical analysis 
Proportions and rates were calculated for categorical data, and continuous data are presented as 
means and s.d., medians and ranges or percentiles (the percentile is the value that divides the 
distribution in such a way that a specific percentage of data is less than or equal to the defined 
percentile), calculated with the National Institute of Standards and Technology (NIST) formula. 
Groups were compared by the χ2 test for categorical variables and by the Wilcoxon rank sum test 
for quantitative variables. To take into account multiple comparisons, the raw P values in group 
comparisons for the salivary samples at fixed times and AUC obtained with Wilcoxon test were 
adjusted with Bonferroni's method. Linear regression analysis was used to examine the relationship 
between salivary cortisol F 1.5 and AUC0–7, and between F 8.5 and AUC7–14. The database was 
managed and statistical analysis performed by SAS 9.1 for Windows (SAS Institute, Inc., Cary, NC, 
USA) or Excel 2010 for Windows. Significance level was set as P<0.05 for all tests.  
Table 2: Percentiles of salivary cortisol concentrations in ng/ml and AUC0–14, AUC0–7, and AUC7–14 in 
patients with secondary AI and in healthy volunteers.  
 
 
 
 
Results 
Percentiles of the six daily salivary cortisol assays, and AUC0–14, AUC0–7, and AUC7–14 for healthy 
volunteers and patients are shown in Table 2. We considered the 2.5th and 97.5th percentiles of 
AUC0–14, AUC0–7, and AUC7–14 in the healthy controls as the lower and upper limits of normality.   
Each patient's salivary cortisol levels are shown in Fig. 1. Their F 0 levels were lower than those in 
controls (P<0.0001) except for four patients with some residual glucocorticoid activity; F 1.5, F 8.5, 
and F 12 levels were higher in patients than in controls (P<0.001, P<0.05, and P<0.01). There were 
no differences between patients and controls in F 7 and F 14 samples. AUC0–14 was significantly 
higher in patients than in controls (P<0.01).  
 
 
  
Figure 1: Salivary cortisol concentrations in patients and in controls. Open circles indicate salivary cortisol 
concentrations in patients and the solid black line indicates their median salivary cortisol levels. Percentiles 
of salivary cortisol in healthy controls are: 2.5th and 97.5th percentiles, short broken lines; 25th and 75th 
percentiles, longer broken lines; 50th percentile, dotted line.  
 
Stratifying the patients by BMI (above or below 25 kg/m2) or sex, we found no differences between 
the groups in terms of single salivary cortisol concentrations, AUC0–14, AUC0–7, or AUC7–14. There 
were no correlations between BMI, WHR, or BSA with the CA dose.  
None of the patients had an AUC0–14 for salivary cortisol below the normal range (considered as the 
2.5th percentile of controls), but 10 of the 28 patients (36%) had an AUC0–14 above the 97.5th 
percentile of normal subjects, with no clear signs or symptoms of glucocorticoid excess. These 
patients also had higher F 1.5 and F 8.5 salivary cortisol levels than the other patients (F 1.5 median 
18.05, range 8.23–27.00 vs median 7.50, range 1.91–14.62 ng/ml, P<0.001; F 8.5 median 10.24, 
range 4.95–24.00 vs median 2.77, range 0.16–7.35 ng/ml, P<0.01), while there was no difference in 
F 0, F 7, and F 14 median salivary cortisol levels, BMI, BSA, or WHR.  
Whenever the patients’ F 1.5 salivary levels were above 11.75 ng/ml (the 97.5th percentile of 
controls), there was a 90% probability of their AUC0–7 being above the 97.5th percentile of normal 
subjects (χ2=9.9556, P<0.001), and logistic regression predicted 94% of AUC0–7 (R
2
 0.94, 
P<0.0001; Fig. 2A). Whenever the F 8.5 salivary cortisol levels were above 6.89 ng/ml (97.5th 
percentile of controls), there was a 70% probability of their AUC7–14 being high as well (Fisher's 
exact test P<0.01), and logistic regression predicted 75% of AUC7–14 (R
2
 0.75, P<0.0001; Fig. 2B).  
 
 
Figure 2: (A) Logistic regression between salivary cortisol F 1.5 and AUC0–7; (B) logistic regression 
between salivary cortisol F 8.5 and AUC7–14.  
All patients were with severe GHD, but only 17 were treated with rhGH. The salivary cortisol levels 
in patients divided into two groups according to whether or not they were on rhGH treatment are 
shown in Fig. 3. We found no significant differences in salivary cortisol concentrations, AUC0–14, 
AUC0–7, or AUC7–14 between these two groups of patients, but we found that the F 1.5 values were 
higher in untreated patients than in those taking rhGH replacement therapy, although the difference 
did not reach statistical significance (Wilcoxon test P=0.07, adjusted with Bonferroni's method 
P=0.66).  
 
 
 
 
Figure 3: Median salivary cortisol concentration of healthy subjects (solid line), compared with patients 
treated with (broken line, n=17) or without (dotted line, n=11) rhGH replacement therapy.  
 
 
Discussion 
Treating primary or secondary AI appropriately remains a challenge, because there is no consensus 
on how to titrate the dosage of replacement therapy to produce cortisol levels that mirror the 
physiological circadian rhythm and to avoid the risk of chronic under- or over-treatment (1, 2).  
Several tools have been proposed to evaluate the adequacy of glucocorticoid replacement therapy, 
but they all have their weakness. Urinary free cortisol excretion fails to detect daily fluctuations of 
cortisol and reveals a marked day-to-day variability depending on renal tubular function (1, 10). A 
clinical score was proposed by Arlt et al. (11), but subsequent studies did not support the 
superiority of this qualitative system over quantitative methods. Mah et al. (3) suggested a single 
serum cortisol measurement 4 h after administering HC, comparing the results with normative data, 
but the study involved only a few patients and has not been replicated in patients taking CA. Some 
studies have methodological weakness, such as the lack of appropriate control group or the 
involvement of patients with both primary and secondary AI, with some endogenous cortisol 
secretion in the latter (3, 11, 18).  
Salivary cortisol is a useful tool for studying disorders of the HPA axis (16) and has been 
previously proposed as a method for assessing glucocorticoid replacement therapy in AI (12, 13, 
14). Some authors have found it to be less useful to measure salivary cortisol in patients taking HC 
replacement therapy (19, 20), though no formal comparison of salivary cortisol levels was drawn 
between patients and healthy controls in these studies. Løvås & Husebye (21) measured salivary 
cortisol levels in patients with Addison's disease receiving a s.c. continuous infusion of 10 mg/m2 
per day of HC with a view to replicating the diurnal rhythm, which is not a practical approach for 
use in outpatients. To our knowledge, there is to date no agreement on monitoring glucocorticoid 
therapy and titrating its dosage (1, 2), in particular when CA is used as replacement therapy.  
We obtained six different saliva collections from healthy controls and patients with secondary AI in 
order to divide the day into two periods of comparable length. We calculated the percentiles of 
normal cortisol concentrations at any time point and the AUC, a mathematical method for 
representing the integrated daily cortisol production in the normal population and the 24-h exposure 
to exogenous cortisol in patients with AI, with an acceptable degree of approximation. The median 
salivary cortisol concentrations and their AUC for patients were between the 2.5th and 97.5th 
percentiles of healthy controls, likely because we administered the modern low-dose glucocorticoid 
replacement therapy. Even though these data could reflect an adequate replacement, salivary 
cortisol peak concentration in patients measured 1.5 h after CA intake was higher than salivary 
cortisol levels in healthy controls at the same time. The modern once-daily HC dual-release tablet 
probably achieved a cortisol profile more similar to healthy subjects, but there is less evidence and 
was found only in primary AI patients treated with this therapy (31). In healthy subjects, the 
salivary cortisol assays reproduced the physiological circadian rhythm of cortisol levels, with higher 
concentrations in the morning that slowly decreased in the hours thereafter and were nearly halved 
at night. The salivary cortisol curve recorded in healthy controls was compared with patients with 
secondary AI taking CA in two fixed doses. If the patients' salivary cortisol levels on waking were 
lower than the 2.5th percentile of healthy controls, we could use this cut-off to indicate AI, as 
recently proposed by Deutschbein et al. (17), even though a few of our patients have some residual 
glucocorticoid activity, as expected in secondary AI. There was no difference between patients and 
controls in the F 7 levels, meaning that patients maintained an adequate glucocorticoid exposure in 
the middle of the day after a fixed dose of CA (12 mg/m2 of CA, equivalent to a HC dose of 
9.6 mg/m2). Since a normal night-time cortisol value excludes hypercortisolism (32), the F 14 
salivary cortisol could be a useful marker of glucocorticoid excess in AI. Our patients on CA had 
lower peak values and a slower decline in cortisol levels than the patients treated with HC, as 
described by Mah et al. (3), though we acknowledge the limited value of comparing results 
obtained in different studies. Should this finding be confirmed in a larger series, however, it could 
represent an advantage of CA therapy, coinciding with fewer adverse events due to acute 
hypercortisolism (hypertension, hyperglycemia).  
In our series of patients, we found no correlation between BMI, WHR, or BSA with the CA dose, 
probably due to the limited number of our series of patients.  
None of our patients had a salivary cortisol AUC0–14 below the 2.5th percentile of healthy controls, 
so we can assume that none of our patients were undertreated. Ten of the 28 patients (36%) showed 
an AUC0–14 above the 97.5th percentile, albeit without any overt signs or symptoms of 
hypercortisolism, and we judged these patients to be overtreated. The AUC may be a reliable tool 
for assessing daily exposure to exogenous glucocorticoids, but it is laborious and impractical in 
routine clinical practice. We could suggest a simplified assessment based on only two saliva 
collections, reflecting the close correlation between F 1.5 and F 8.5 salivary cortisol levels and the 
AUC, both of which enabling the same distinction between well- and overtreated patients. Salivary 
cortisol samples collected 1 h and 30 min after the morning and afternoon doses of CA could 
pinpoint the majority of overtreated patients (90 and 70%, based on the morning and afternoon 
doses respectively).  
Another point to note concerns co-treatment with rhGH: 11β-HSD1 activity is enhanced in GHD, 
leading to a higher tissue exposure to glucocorticoids, so there may be differences in cortisol 
exposure in patients treated with CA or HC in association with rhGH therapy, which inhibits the 
metabolism of cortisone into cortisol (8, 9, 23). In secondary AI, other replacement therapies (rhGH 
or gonadal steroid hormones) may raise cortisol-binding globulin levels, another reason for the 
superiority of salivary measurements to assess cortisol profiles in secondary AI (7, 8, 9). We 
showed that salivary cortisol levels after the morning dose of CA were higher in patients with GHD 
not treated with rhGH (though not to a statistically significant degree in our sample, possibly 
because of its limited size or of a random effect). Further studies in a larger series of patients with 
GHD not taking rhGH are needed to confirm whether these patients should be treated with lower 
doses of CA.  
In summary, we assessed the circadian cortisol profile by means of multiple round-the-clock 
salivary cortisol collections from healthy controls and patients taking CA for secondary AI. Our 
study cannot support any general hypotheses due to the limited sample size and the lack of any 
long-term follow-up to assess the clinical impact of dose titration based on our data. On the other 
hand, the number of salivary collections can be restricted to just 2 per day, because cortisol levels 
measured 1 h and 30 min after each CA dose adequately predicts the whole daily curve. These 
results thus pave the way to a future application of salivary cortisol assays for assessing the 
adequacy of replacement therapy in outpatients with secondary AI.  
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Table 1  
Clinical details of the patients. 
No. Sex Age Hypopituitarism Type of deficit Replacement therapy 
1 F 47 Empty sella A, T, G, S CA, rhGH, T4, ST  
2 M 65 Post-RT A, T, G, S CA, rhGH, T4, ST  
3 F 54 Post-RT A, T, G CA, rhGH, T4 
4 M 58 Post-surg+RT A, G CA, rhGH 
5 M 39 Empty sella A, T, G, S CA, rhGH, T4, ST  
6 F 62 Empty sella A, T, G CA, rhGH, T4 
7 M 48 Post-surg+RT A, T, G, S CA, rhGH, T4, ST  
8 M 48 Post-surg+RT A, T, G, S CA, rhGH, T4, ST  
9 F 52 Post-surg+RT A, T, G CA, rhGH, T4 
10 M 56 Post-surg+RT A, T, G, S CA, rhGH, T4, ST  
11 M 45 Post-surg A, T, G, S CA, rhGH, T4, ST  
12 F 23 Post-surg+RT A, T, G, S CA, rhGH, T4, ST  
13 F 23 Post-surg A, T, G, S CA, rhGH, T4, ST  
14 M 57 Post-surg A, T, G, S CA, rhGH, T4, ST  
15 M 58 Post-surg A, T, G, S CA, rhGH, T4, ST  
16 M 21 Congenital hypoplasia A, T, G CA, rhGH, T4 
17 F 24 Congenital hypoplasia A, T, G, S CA, rhGH, T4, ST  
18 M 75 Parasellar meningioma A, T, G CA, T4 
19 F 68 Post-surg A, T, G CA, T4 
20 M 72 Post-surg A, T, G, S CA, T4, ST  
21 F 78 Empty sella A, T, G CA, T4 
22 M 76 Post-surg+RT A, T, G, S CA, T4, ST  
23 M 66 Post-surg A, T, G, S CA, T4, ST  
24 F 31 Hydrocephalus A, T, G CA, T4 
25 M 65 Post-surg A, T, G, S CA, T4, ST  
26 M 58 Post-surg A, T, G, S CA, T4, ST  
27 M 74 Post-surg A, T, G, S CA, T4, ST  
28 F 76 Post-surg+RT A, T, G CA, T4 
 Surg, surgery; RT, radiotherapy; A, secondary adrenal insufficiency; T, secondary thyroid 
insufficiency; G, severe GH deficiency; S, secondary hypogonadism; CA, cortisone acetate; 
rhGH, recombinant human GH; T4, levothyroxine; ST, sex hormone therapy.  
 
 
 
 Table 2  
Percentiles of salivary cortisol concentrations in ng/ml and AUC0–14, AUC0–7, and AUC7–14 in 
patients with secondary AI and in healthy volunteers.  
 
2.5 25 50 75 97.5 
F 0 
     
 Patients 0.13 0.84 1.54 2.45 9.72 
 Controls 3.25 5.74 7.44 10.37 15.73 
F 1.5 
     
 Patients 1.81 5.82 11.52 15.88 25.82 
 Controls 2.02 3.77 5.14 6.71 11.75 
F 7 
     
 Patients 0.19 1.10 2.31 3.94 8.73 
 Controls 0.45 1.89 3.80 4.87 7.91 
F 8.5 
     
 Patients 0.80 2.33 5.50 8.96 22.99 
 Controls 0.65 2.42 3.28 4.22 6.89 
F 12 
     
 Patients 0.63 2.08 3.09 9.55 13.00 
 Controls 0.08 0.96 2.15 2.92 4.61 
F 14 
     
 Patients 0.53 1.26 2.11 3.08 6.31 
 Controls 0.09 0.97 1.63 2.23 4.68 
AUC0–14      
 Patients 1339 3536 4860 6759 10 374 
 Controls 1180 2064 3073 4107 5926 
AUC0–7      
 Patients 865 1755 3071 3886 6172 
 Controls 817 1479 2100 2722 3943 
AUC7–14      
 Patients 488 1109 1850 3020 5315 
 Controls 165 753 1114 1533 1997 
 
 
